Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Cancer Res. 2020 Oct 6;80(23):5344–5354. doi: 10.1158/0008-5472.CAN-19-0677

Fig. 1. Inhibitors of XPO1 sensitize human parental MM cell lines and MEL-resistant cell lines to MEL.

Fig. 1.

(A) H929 (3 × 106 cells/mL), 8226 (2 × 106 cells/mL), and U266 (4 × 106 cells/mL) human MM cells were treated for 20 hours with SEL (300 nM) or ELT (300 nM) as single agents (control) or the cells were treated with SEL or ELT combined with MEL (15 μM) (n=3). (B) Human 8226 MM cells were treated with SEL (300 nM) or KOS-2464 (10 nM) +/− MEL and assayed for apoptosis (n=3). (C/D) Human 8226 and U266 drug-resistant (8226-LR5 and U266-LR6) and parental MM cell lines were treated for 20 hours with MEL alone (VC) or with SEL (300 nM), ELT (300 nM), or KOS-2464 (10 nM) concurrent with 10 or 20 μM MEL and assayed for apoptosis by flow cytometry (using activated caspase 3) (n = 5).